US researchers have begun the first-in-human study evaluating experimental treatment for Ebola virus disease, the National Institute of Health's (NIH) Clinical Center said in a statement
The clinical phase Named VRC 608, investigates the safety and tolerability of a single monoclonal antibody called mAb114, developed by an Ebola survivor.
The researchers plan to enroll 18 to 30 healthy volunteers aged between 18 and 60 years. The study will not expose the participants to the Ebola virus.
"We hope that this study confirms the safety of this experimental treatment of the Ebola virus disease ̵
"Ebola is very deadly, and reports of another outbreak in the Democratic Republic of the Congo (DRC) remind us that we urgently need Ebola treatments."
The study complements the NIAID's efforts to develop scientifically and ethically-based biomedical research to develop countermeasures against Ebola virus disease. "Fauci added:
MAb114 is a monoclonal antibody-a protein that binds to a single target of a pathogen-isolated from a human survivor of the 1995 Ebola outbreak in a city in the Democratic Republic of Ko ngo.
The NIAID discovered that the survivors retained antibodies against Ebola 11 years after infection.
They isolated the antibodies and tested the most favorable ones in laboratory and non-human primate studies and selected mAb114 to be the most promising
Researchers showed that MAb114 binds to the elusive core of the Ebola virus surface protein and reduces the interaction of the Blocked protein with its receptor on human cells.
A single dose of mAb114 protected non-human primates days after a fatal Ebola virus infection
In the study, which was due to be fully enrolled in July 2018, the first three participants received an intravenous infusion of mAb114 of 5 milligrams each Kilograms for 30 minutes.
The team will evaluate safety data to determine if the remaining participants can receive higher doses (25 mg / kg and 50 mg / kg).
Participants are bled before and after the infusion, and are brought home with a diary card to measure their temperature (19659002) Participants visit the clinic approximately 14 times within six months to collect their blood see if mAb114 is detectable and screened for any health changes, the report said.
Ebola viral disease is a serious and often deadly disease that can cause fever, headache, muscle aches, weakness, fatigue, diarrhea, vomiting, stomach pain and bleeding (severe bleeding)
Not discovered until 1976 in humans in the Democratic Republic of the Congo The largest outbreak occurred in West Africa from 2014 to 2016, causing more than 28,600 infections and more than 11,300 deaths, according to the World Health Organization.
In May 2018, the DRC reported a new Ebola outbreak. While approved treatments for Ebola virus disease are still unavailable, several experimental therapies are being developed.
rt / ksk
(This story was not edited by Business Standard employees and is automatically generated from a shared feed.)